Mantle Cell Lymphoma Archives

Press
12/11/2023

Venetoclax with standard chemo-immunotherapy induced a high response rate as first-line treatment for mantle cell lymphoma and was generally well tolerated, a PrECOG early-phase trial shows

Trial PrE0405 met its primary endpoint. Venetoclax combined with bendamustine+rituximab as the first therapy for MCL in patients over age 60 led to a complete response rate of 85%. The American Society of Hematology 2023 annual meeting featured the data. The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate […]

Trial Activation
5/24/2018

PrE0404 – Active

Now Open to Enrollment: PrE0404 A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma. NCT03323151

We are always evolving in an ever-changing industry.

Venetoclax with standard chemo-immunotherapy induced a high response rate as first-line treatment for mantle cell lymphoma and was generally well tolerated, a PrECOG early-phase trial shows

PrE0404 – Active

Categories

We are always evolving in an ever-changing industry.

Venetoclax with standard chemo-immunotherapy induced a high response rate as first-line treatment for mantle cell lymphoma and was generally well tolerated, a PrECOG early-phase trial shows

PrE0404 – Active

Categories

Tags